Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NWRD09 in Persistent Cervical HPV16 Infection
NCT07710703Recruiting
- Sponsor
- Newish Biotechnology
- Start
- Feb 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Randomised, double-blind trial in persistent human papillomavirus 16 infection comparing NWRD09 with Placebo (2 arms). Primary endpoint: Proportion of participants with virologically-proven clearance of HPV 16 at 16 weeks. Started Feb 2026; status: recruiting.
02
Drugs
NWRD09
03
Conditions
persistent human papillomavirus 16 infection
Beyond the preview
Go deeper on NCT07710703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07710703.